Vargas AO, Luna RR, Garcia MP, Cardos RC, Hidalgo LV, Jácome DL, Gutiérrez MC. Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation.
Rev Bras Hematol Hemoter 2013;
35:343-6. [PMID:
24255618 PMCID:
PMC3832315 DOI:
10.5581/1516-8484.20130099]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Accepted: 07/20/2013] [Indexed: 12/01/2022] Open
Abstract
Background
In childhood cancer, consolidation treatment with chemotherapy followed by
autologous hematopoietic progenitor stem cell transplantation is currently an
accepted treatment modality in patients with high-risk solid tumors or in patients
who have relapsed after conventional treatment.
Objectives
The objective of this study was to describe the results of transplantation of a
group of children who had high-risk solid tumors or relapsed after conventional
chemotherapy regimens.
Methods
A retrospective analysis was conducted from January 1998 to October 2004 of all
children with pathologic diagnoses of high-risk solid tumors or children that had
previously relapsed after conventional chemotherapy and that were subsequently
submitted to autologous hematopoietic progenitor stem cell transplantation. The
analysis included overall survival rates, event-free survival rates, mortality
rates and chemotherapy complications.
Results
Nineteen patients were submitted to this approach. The age range was from 27 to
196 months with a median age of 52 months. The overall survival rate at 100 days
was observed in 79%, the three-year event-free survival rate was 63%. The
mortality rate secondary to the myeloablative chemotherapy regimen was 21% (n =
4). Only three patients (15.8%) relapsed with tumor progression after transplant.
Conclusion
Autologous hematopoietic progenitor stem cell transplantation is still a
successful procedure in patients with solid tumors refractory to conventional
chemotherapy.
Collapse